SLI
2.140,82
PKT
+8,17
PKT
+0,38
%
Werbung
Analysen zu SLI-Werten
| Datum | Rating | Analyst | |
|---|---|---|---|
| 12.06.12 | UBS neutral | UBS AG | |
| 12.06.12 | Julius Bär buy | UBS AG | |
| 12.06.12 | UBS sell | Société Générale Group S.A. (SG) | |
| 12.06.12 | Swiss Life buy | Nomura | |
| 12.06.12 | UBS hold | Société Générale Group S.A. (SG) | |
| 11.06.12 | Nestlé hold | Société Générale Group S.A. (SG) | |
| 11.06.12 | UBS hold | Commerzbank Corp. & Markets | |
| 11.06.12 | Novartis hold | Vontobel Research | |
| 08.06.12 | Novartis neutral | J.P. Morgan Cazenove | |
| 08.06.12 | ABB (Asea Brown Boveri) buy | Citigroup Corp. | |
| 08.06.12 | UBS buy | WestLB AG | |
| 08.06.12 | Logitech neutral | Sarasin Research | |
| 08.06.12 | Logitech hold | Vontobel Research | |
| 06.06.12 | Holcim neutral | Goldman Sachs Group Inc. | |
| 06.06.12 | Holcim sell | Goldman Sachs Group Inc. | |
| 06.06.12 | Geberit hold | Vontobel Research | |
| 05.06.12 | Straumann underperform | Exane-BNP Paribas SA | |
| 05.06.12 | Novartis hold | Vontobel Research | |
| 04.06.12 | Novartis neutral | Exane-BNP Paribas SA | |
| 04.06.12 | Swiss Re neutral | Exane-BNP Paribas SA | |
| 04.06.12 | Novartis neutral | Citigroup Corp. | |
| 04.06.12 | Straumann hold | Vontobel Research | |
| 04.06.12 | Novartis hold | Vontobel Research | |
| 04.06.12 | Zurich Insurance buy | Vontobel Research | |
| 01.06.12 | Swiss Re buy | UBS AG | |
| 01.06.12 | Swiss Re hold | Société Générale Group S.A. (SG) | |
| 01.06.12 | Kühne + Nagel International underperform | Cheuvreux SA | |
| 01.06.12 | Lonza hold | Vontobel Research | |
| 31.05.12 | Swiss Re overweight | J.P. Morgan Cazenove | |
| 31.05.12 | ABB (Asea Brown Boveri) neutral | Exane-BNP Paribas SA | |
| 31.05.12 | Swiss Re buy | Sarasin Research | |
| 31.05.12 | Swiss Re add | Commerzbank Corp. & Markets | |
| 31.05.12 | Holcim overweight | Morgan Stanley | |
| 31.05.12 | Holcim equal-weight | Morgan Stanley | |
| 31.05.12 | Swiss Life hold | Société Générale Group S.A. (SG) | |
| 31.05.12 | Swiss Re buy | Vontobel Research | |
| 31.05.12 | Novartis buy | Deutsche Bank AG | |
| 30.05.12 | Novartis outperform | Credit Suisse Group | |
| 30.05.12 | Holcim outperform | Exane-BNP Paribas SA | |
| 29.05.12 | Novartis neutral | J.P. Morgan Cazenove |